Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03795675 · ClinicalTrials.gov registry record · NA

CI Following VS Removal or Labyrinthectomy

A NA study of Vestibular Schwannoma and Meniere Disease, sponsored by Ohio State University.

Recruiting
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT03795675: Recruiting NA study of Vestibular Schwannoma and Meniere Disease, sponsored by Ohio State University.

NCT03795675 is a NA study of Vestibular Schwannoma and Meniere Disease that is actively recruiting participants, run by Ohio State University. The registered enrollment target is 15 participants, below the 50-participant average among 7 other Vestibular Schwannoma trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03795675, a NA study of Vestibular Schwannoma and Meniere Disease, is actively recruiting participants, sponsored by Ohio State University.

RECRUITING
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This study is a prospective, clinical study to determine if it is safe and effective to use a cochlear implant over time in individuals undergoing removal of a vestibular schwannoma (VS), benign tumor of the hearing and balance nerve or undergoing a labyrinthectomy for treatment of Meniere's disease. Individuals undergoing these surgeries will be deaf on the surgical side after the procedure. Currently, cochlear implants are approved for use and not considered investigational in individuals with hearing loss on both sides. However, use of a cochlear implant for these patient populations (single-sided hearing loss) will be considered a new use of an approved device. Participants undergoing surgery to remove a VS or having a labyrinthectomy will have a cochlear implant inserted after the surgical procedure for clinical care. Approximately 4 weeks after surgery, participants will be fitted with an external speech processor on the surgical side that will stimulate the internal cochlear implant. Participants will return at the following intervals after the initial processor fitting: 2 weeks, 1 month, 3 months, 6 months, 9 months, and 12 months. At each interval, participants will complete questionnaires on how they are hearing with the implant and their quality of life with the implant and be tested on their ability to hear sounds and understand speech. Potential risks are those associated with all cochlear implant surgeries, and include device failure resulting in removal of device, irritation or redness in surgical area and/or area where processor is attached, increased ringing in the ear, facial nerve stimulation and a change in the way speech and other sounds sound through the implant. Potential benefits to individual participants in this study include improvement in detection and speech understanding of the surgical ear. Participants may also experience improved abilities to locate sound and understand speech in noise as the result of having hearing on both sides.

Primary Outcome

Sounds that vary in pitch (frequency) will be presented in a sound field to identify hearing thresholds in decibels (dB). Participant indicates when a sound is detected/perceived when listening with the cochlear implant. The softest sound at each specific frequency (125, 250, 500, 1000, 2000, 3000, 4000, 6000, 8000 Hertz (Hz)) will be recorded in dB hearing level.

Interventions

  • DEVICE Cochlear Implant

Study Locations (1)

Ohio

  • The Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2019-01-14
Est. Completion 2027-12-31
Phase NA
Ohio State University

552 total trials

What NCT03795675 shows while recruiting

NCT03795675 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 50-participant average among 7 other Vestibular Schwannoma trials with a reported enrollment target (70% lower).

The record links to 2 conditions, with Vestibular Schwannoma appearing as the primary indexed condition, and to 1 intervention - of which Cochlear Implant is the first listed.

NCT03795675 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT03795675 about?

NCT03795675 is a clinical study titled "CI Following VS Removal or Labyrinthectomy". This study is a prospective, clinical study to determine if it is safe and effective to use a cochlear implant over time in individuals undergoing removal of a vestibular schwannoma (VS), benign tumor of the hearing and balance nerve or undergoing a labyrinthectomy for treatment of Meniere's disease...

What is the current status of trial NCT03795675?

This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2019-01-14. Estimated completion is 2027-12-31.

What conditions does trial NCT03795675 study?

This clinical trial studies the following conditions: Vestibular Schwannoma, Meniere Disease.

What interventions are being tested in trial NCT03795675?

The interventions under investigation include: Cochlear Implant (DEVICE).

Who is sponsoring clinical trial NCT03795675?

This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03795675 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Vestibular Schwannoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03795675, the US trial registry maintained by the National Library of Medicine. NCT03795675 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.